Employees: 986
Size Oxford BioMedica (OXB.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $841M, the 233rd largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £527.00 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -15.8% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 9th highest of 19 in its peer set.
Growth Revenue grew 16.0% over the last twelve months (peer median +1.8%); the operating margin is -18.2% (peer median -28.8%).
Valuation It trades at 4.1× enterprise value to sales against a peer median of 6.6× (6th cheapest of 18).
Capital Return on invested capital runs 33.5 points below its cost of capital (16.5% WACC).
Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £175M | £169M | £129M | £89.5M | £140M |
| Revenue growth | — | +31% | +44% | -36% | — |
| Gross profit | £62.7M | £65.3M | £52.4M | £39.2M | £69.1M |
| EBITDA | -£13.3M | -£9.12M | -£23.3M | -£60.1M | -£28.3M |
| Net income | -£40.7M | -£30.1M | -£43.2M | -£157M | -£39.2M |
| Free cash flow | -£32.5M | -£6.46M | -£58.1M | -£38.2M | -£33.0M |
| Capital expenditure | £10.4M | £4.76M | £7.50M | £9.83M | £16.3M |
| Total debt | n/a | £148M | £109M | £111M | £114M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OXB.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | -7.2% | 6th highest of 21 |
| 6-month return | -14.7% | -15.8% | 9th highest of 19 |
| Distance from 52-week high | -45.2% | -42.8% | 10th lowest of 21 |
| Revenue growth (TTM) | +16.0% | +1.8% | 7th highest of 17 |
| Operating margin | -18.2% | -28.8% | 7th highest of 18 |
| EV / Sales | 4.1× | 6.6× | 6th cheapest of 18 |
| ROIC minus cost of capital | -33.5 pp | -7.0 pp | 3rd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |